GeoVax Labs, Inc.
0.5526-0.05 (-7.81%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · GOVX · USD
Key Stats
Market Cap
16.42MP/E (TTM)
-Basic EPS (TTM)
-0.93Dividend Yield
0%Recent Filings
8-K
Nasdaq bid price deficiency
GeoVax Labs received a Nasdaq deficiency notice on July 31, 2025, for its common stock's closing bid price lingering below $1.00 over 30 consecutive business days, breaching the minimum listing rule. The company has until January 27, 2026, to lift the price above $1.00 for 10 straight business days and regain compliance. Nasdaq listing remains intact for now. Delisting looms if they fail, potentially via reverse stock split.
8-K
GeoVax Q2 loss, pipeline advances
GeoVax Labs reported a Q2 2025 net loss of $5.4 million, or $0.35 per share, amid $852 thousand in government contract revenue from its BARDA award, which was terminated for convenience. Yet clinical progress shone: EMA guidance cleared a streamlined Phase 3 path for GEO-MVA mpox/smallpox vaccine, starting 2H 2026, while GEO-CM04S1 showed superior T-cell responses in CLL patients versus mRNA vaccines. Cash dipped to $3.1 million, bolstered by $5.6 million from a July offering. BARDA termination risks funding continuity.
10-Q
Q2 FY2025 results
GeoVax Labs posted Q2 revenue of $852K from its government contract, up sharply from $301K a year ago, while YTD revenue hit $2.5M versus $301K last year—yet the BARDA deal ended abruptly in April for convenience. Operating losses widened to $5.4M from $5.1M y/y, driven by higher R&D on Gedeptin and GEO-MVA programs, with net loss at $5.4M or $0.35 per share on 15.4M weighted shares; YTD, losses narrowed slightly to $10.7M from $10.9M, EPS improving to $(0.79) from $(4.68) thanks to share issuances. Cash burned to $3.1M by quarter-end after $7.9M raised via offerings, with free cash flow negative at $(10.3M) from operations minus minimal capex. Stockholders approved a new incentive plan in June. BARDA termination stings, but clinical momentum builds.
8-K
GeoVax raises $6M in unit offering
GeoVax Labs closed a public offering on July 2, 2025, issuing 9.2 million common units at $0.65 each, including shares and warrants to buy 18.5 million more shares at the same price over five years. Net proceeds of about $5.6 million will fund working capital and corporate needs, while a 60-day lockup bars new stock issuances and a six-month ban hits variable-rate deals. Fresh cash bolsters the biotech's runway amid clinical trials. Warrants add upside, but dilution looms large.
8-K
GeoVax annual meeting outcomes
GeoVax Labs stockholders convened their annual meeting on June 5, 2025, electing seven directors including Randal D. Chase and David A. Dodd amid 4.4 million broker non-votes. They greenlit the 2025 Stock Incentive Plan and Nasdaq-compliant issuance of up to 3.4 million shares from a March warrant, while ratifying Wipfli LLP as auditors. Votes reflected solid support, yet low turnout signals engagement gaps. Directors serve until the next meeting.
BVAXD
BioVaxys Technology Corp.
0.15-0.03
CVAC
CureVac N.V.
5.38+0.01
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
MRNA
Moderna, Inc.
24.70-0.65
NNVC
NanoViricides, Inc.
1.86+0.33
NVAX
Novavax, Inc.
8.38-0.14
VIR
Vir Biotechnology, Inc.
5.91-0.52
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
VRAX
Virax Biolabs Group Limited
0.60+0.01
VXRT
Vaxart, Inc. - Common Stock
0.35+0.00